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Abstract 
Background: Endometriosis is a common hormone-dependent gynecologic disease 
with a high recurrence. Laparotomy or laparoscopy is the standard surgery for the 
large endometrioma. Also, sclerotherapy is basically used to treat different diseases 
one of which is endometrioma. 
Objective: The study was designed to assess the value of transvaginal ultrasound-
guided ethanol sclerotherapy in patients with a recurrent endometrioma. 
Materials and Methods: In a randomized clinical trial, an interventional group of 
20 patients underwent transvaginal ethanol sclerotherapy for recurrent ovarian 
endometrioma. The patients were followed up first after one and two weeks and then 
after one, two, and three months. If the patients had no endometrioma, they were 
treated with in vitro fertilization (IVF) (standard long protocol). A control group of 
20 patients with endometrioma were enrolled for an IVF protocol. They had no 
treatment by ethanol sclerotherapy. IVF parameters, pregnancy rates, and 
implantation rates were compared in both groups. 
Results: The demographic data showed no difference between the two groups. The 
initial mean endometria size was 41.45±15.9 cm, the recurrence rate after 6 months 
was 4 (20%), FSH before and after sclerotherapy was 6.97±2.25 IU/L and 6.78±1.88 
IU/L (p=0.343). The clinical pregnancy rate was 6 (33.3%) vs. 3 (15%), (p=0.616). 
The fertilization rate emerged 63.06% in study group vs. 60.38%, (p=0.57). The 
implantation rate turned out 12.9% in study group vs. 7.5%, (p=0.52). None of these 
results were significant. However, the data pointed to a better trend toward the 
ethanol sclerotherapy group. 
Conclusion: Ethanol sclerotherapy could be an effective strategy for the treatment 
of recurrent endometrioma especially before IVF. 
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Introduction 
 
ndometriosis is a general estrogen-
needy disorder with a significant 
recurrence rate (1). Several medical 
methods are available to treat endometriosis. 
The current evidence is insufficient to support 
the superiority of one treatment over another 
(2). However, medicinal treatment has proved 
to be of less benefit than surgical treatment for 
infertile women. On the other hand, ovarian 
surgery may reduce ovarian reserves in 
women with an advanced disease (3). 
The surgical removal of endometrioma may 
cause not only the removal of healthy ovarian 
tissue but also surgery-related local 
inflammation or vascular compromise, which 
may have a harmful effect on the residual 
primordial follicle pool. Actually, the bilateral 
removal of endometrioma by laparoscopy 
caused a premature ovarian failure at a 2.4% 
risk (Busacca et al 2006). Reportedly, this is 
one of the reasons why sclerotherapy is 
another option beside laparotomy or 
laparoscopy. Researchers have shown that 
the surgical treatment of endometrioma has 
no considerable impact on in vitro fertilization 
(IVF) pregnancy rates and ovarian response 
after stimulation (4). Juan et al recommend 
keeping on straight to IVF to decrease time of 
pregnancy, to diminish surgical complications 
and to lower the costs. Surgery should be 
considered only for large cysts or painful 
disorders which are intractable to medical 
handlings, or once malignancy cannot 
consistently be excluded (5). One of the other 
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treatments for endometrioma is ultrasound-
guided aspiration. After a simple aspiration, 
the recurrence rate has been up to 100%; 
however, repeated aspiration of 
endometrioma is another suggestion (6).  
Studies have reported that a combination 
of aspiration and sclerosing agent could be 
effective at reducing the recurrence rate (7-
10) on the other hand, Kafali et al studied high 
recurrence rate in cyst with a bloody aspirate 
and high CA125 levels in cyst fluid (11). It 
seems that the precision of transvaginal ultra 
sonography is acceptable for discovering the 
type of ovarian cysts without any fright from 
malignancy or complication (12).  
Another application of sclerotherapy is for 
simple cysts that are painful or liable to 
torsion. Such patients, who are at a low risk of 
malignancy, are relieved with sclerotherapy 
while avoiding surgery (13). Moreover, the 
aspiration of basal cysts does not improve 
ART outcome when E2 levels are suppressed 
(14). Ethanol retention in chocolate cysts 
guided by ultrasound is a therapeutic 
approach with a high cure rate. Some 
researchers have pointed out that ethanol is 
left for five to ten minutes. Also, some others 
have reported that effective sclerotherapy 
occurs, when ethanol is retained in the 
endometrioma (8, 9, 15-19).  
In this study, we comparatively investigated 
the IVF outcome in the recurrent 
endometrioma with and without ethanol 
sclerotherapy and the recurrence rate after 
alcohol treatment. 
 
Materials and methods 
 
In a prospective randomized clinical trial 
(figure 1), 40 patients participated between 
March 2011 and February 2012 after they 
provided a written informed consent. This 
study was approved by the Committee of 
Ethics of Yazd Research and Clinical Center 
for infertility affiliated to Shahid Sadoughi 
University of Medical Sciences. 
Randomization was done, besides using 
computerized randomization, by opening 
sealed envelopes.  
The inclusion criteria were FSH<10, 
20<age<39 years, past history of operation on 
endometrioma which recurrent unilateral 
endometrioma was occurred again and 
recurrent endometrioma more than 30 mm. 
The exclusion criteria were liver or kidney or 
heart diseases and sever male factor 
infertility. The diagnosis of endometrioma was 
based on sonography and the result of 
previous laparotomy/laparoscopy. 
Twenty patients, assigned as the 
interventional group, received transvaginal 
sclerotherapy for ovarian endometrioma. In 
the operation room, the patients received 
pentazocin (Ampulla, 30 mg/ml, Tolidaru, Iran) 
and pethedine (Ampulla, 50 mg/ml, Kaspian, 
Iran) as analgesic agents. Cefixim 400 mg/day 
was started as a prophylactic antibiotic before 
and after sclerotherapy for one week. A 
needle (three-way needle, Wallace, UK) was 
introduced into the endometrioma and 
aspiration was done under sonography 
guidance (Honda 4000, Japan). 
The endometrioma was irrigated with a 
sterile normal saline till the fluid was clear in 
color. The endometrioma was filled with 98% 
ethanol for 10 minute and at the end ethanol 
was aspirated. The volume of ethanol was 
calculated 80% of the aspirated 
endometrioma fluid .Then fluid was sent for a 
cytological test for all the patients. Then the 
patients were followed up after one week, 
one, two, and three months.  
After three months, if the patients had no 
complication or endometrioma, along IVF 
protocol was started. The IVF protocol was 
started for the control group without 
sclerotherapy. All the patients underwent 
pituitary desensitization (FSH ≤5 IU/ml, LH ≤5 
IU/ml, Estradiol ≤50 pg/ml, and 
progestrone≤1ng/ml) with suprefact (Buserelin 
acetate, Aventis Pharma Deutschland, 
Germany) at a dose of 0.5µg/day initiated in 
the mid luteal phase. It continued after 
menstruation at a dose of 0.25µg/day until the 
day of U-HCG administration.  
Gonal-F (Gonal-F, Serono, Italy) was 
initiated from the second day of menses 
according to the patient's age and antral 
follicular count. Then, the dose of Gonal-F 
was adjusted for follicular monitoring by 
sonography and estradiol. First, sonography 
was done on the seventh day of menstruation 
and repeated as needed .When the follicular 
size reached 18-20 mm, HCG (pregnyl, 
Daropakhsh, Iran)10000 IU was administered. 
After 34-36 hours, a transvaginal ultrasound-
guided ovum pick-up was performed.  
Two fresh embryo transfers were 
performed on the third day after ICSI with a 
Labotect catheter (Labotect, Gotting, 
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Germany). The luteal phase was supported by 
Cyclogest (Actavis, Barnstaple, EX32 8NS, 
UK) vaginally 400 mg/ two times per day. It 
was started on the day after the oocyte 
retrieval. Serum βhCG was checked 14 days 
after the embryo transfer. If the patient was 
pregnant; Cyclogest was continued till the 
tenth week of gestation. Clinical pregnancy 
was confirmed by transvaginal sonography 
with at least one gestational sac in the uterine 
cavity. Recurrence would be anticipated 
during 6 months if there was any 
reappearance of endometrioma according to 
vaginal ultrasonography in non-pregnant 
patients. Finaly, IVF parameters, fertilization 
rates and implantation rates were compared in 
the two groups. 
 
Statistical analysis 
Statistical analysis was performed with a 
SPSS software (version 16).The significance 
of differences was statistically checked by t-
test, paired t-test, Mann-Witney and χ2-test. 
P<0.05 was considered statistically significant. 
 
 
 
 
Figure 1. Consort flow diagram. 
 
Results 
 
Forty patients who met the inclusion criteria 
of the study were randomly divided into two 
groups. The size of the endometrioma was 
41.45±15.9 (cm). Malignant cells were not 
seen in the pathology report of aspirated 
endometrial fluid. No complication occurred in 
any patient. The endometrioma recurred in 4 
(20%) patients after 6-months post 
sclerotherapy.  
No difference was seen between the two 
groups in terms of mean age, duration of 
infertility, FSH, LH, TSH and antral follicular 
count (AFC) (Table I). FSH was checked on 
the second day before (6.97±2.25 IU/ml) and 
3 month after (6.78±1.88 IU/ml) sclerotherapy 
(p=0.343). The IVF outcome was compared in 
both groups (Table II).  
There were no significant differences with 
regard to the total dosage of gonadotropin 
(p=0.866), estradiol on the day of HCG 
(p=0.874), duration of gonadotropin 
consumption (p=0.553), total number of 
follicles (p=0.331), oocytes and embryos, 
number of transferred embryos, and 
Metaphase II oocytes (p=0.476). Good-quality 
embryos were achieved in 94.4% and 50% of 
Assessed for eligibility (n= 40) 
Excluded (n=0) 
 Not meeting inclusion criteria (n=0) 
 Declined to participate (n=0) 
 Other reasons (n=0) 
Analysed (n= 20) 
Excluded from analysis (give reasons) (n= 0) 
Lost to follow-up (give reasons) (n= 0) 
 Discontinued intervention (give reasons) (n= 0) 
Allocated to intervention (n= 20) 
 Received allocated intervention with ethanol 
sclerotherapy (n=20) 
 Did not receive allocated intervention (give reasons) 
(n= 0) 
Lost to follow-up (give reasons) (n= 0) 
 Discontinued intervention (give reasons) (n= 0) 
Allocated to intervention (n= 20) 
 Received allocated intervention without ethanol 
sclerotherapy (n= 20) 
 Did not receive allocated intervention (give reasons) 
(n= 0) 
Analysed (n=20) 
Excluded from analysis (give reasons) (n= 0) 
Allocation 
Analysis 
Follow-Up 
Randomized (n=40) 
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the study group and the control group 
respectively (p=0.003). Chemical pregnancy, 
clinical pregnancy fertilization and 
implantation rate were described in the study 
and control groups as 6 (33.31%) vs. 4 (20%) 
p=0.468, 5 (27.8%) vs. 3 (15%) p=0.616, 
63.06% vs. 60.38% p=0.57, and 12.91% vs. 
7.5% p=0.52 respectively. 
 
 
 
Table I. Baseline patient characteristics 
 Study group 
Mean ± SD 
Control group 
Mean ± SD 
p-value 
Age (years) 
 
29.4 ± 5.76 31 ± 3.89 0.231 
Duration of infertility (years) 
 
5.05 ± 2.85 6.5 ± 2.81 0.072 
FSH (IU/ml) 
 
6.97 ± 2.25 6.64 ± 2.44 0.565 
LH (IU/ml) 
 
5.83 ± 2.18 6.03 ± 2.07 0.862 
TSH (mIU/L) 
 
2.53 ± 0.8 2.14 ± 0.64 0.149 
Antral follicular count(number) 
 
8.8 ± 1.6 8.25 ± 2.1 0.369 
Mann-Witney and t-test, p-value <0.05 significant 
 
 
Table II. Comparison of IVF outcomes in both groups 
 Mean ± SD 
Study group 
Mean ± SD 
Control group 
p-value 
Total dose of gonadotropin (IU) 
 
2491.6 ± 662.6 2523.7 ± 499.4 0.866 
Estradiol (On the Day of HCG) 
 
1466.6 ± 1367.6 1280 ± 892.8 0.874 
Duration of gonadotropin 
 
8.94 ± 1.21 9.65 ± 2.25 0.553 
NO. of Follicle 
 
10.5 ± 3.88 9.4 ± 3.39 0.331 
NO. of total oocyte 
 
7.83 ± 2.22 7.55 ± 4.77 0.393 
NO. of total embryo 
 
4.72 ± 2.76 3.8 ± 2.56 0.319 
NO. of embryo transfer 
 
2.17 ± 0.7 2.35 ± 0.67 0.331 
NO. of Metaphase II oocyte 
 
6.11 ± 2.34 5.45 ± 3.18 0.476 
NO= Number, Mann-Witney and t-test, p-value <0.05 significant,   HCG=Human Chorionic Gonadotropin. 
 
 
 
Table III. Comparison of pregnancy results in both groups 
 Study group 
No (%) 
Control group 
No (%) 
p-value 
Chemical pregnancy 
 
6 (33.3%) 4 (20%) 0.468 
Clinical pregnancy 
 
5 (27.8%) 3 (15%) 0.616 
Fertilization rate 
 
63.06% 60.38% 0.57 
BMI (kg/m2) 
 
25.00±3.2 24.30±3.6 0.557 
NO=Number, Mann-Witney and t-test, p-value <0.05 significant 
 
Discussion 
 
We found that ethanol sclerotherapy is a 
safe and alternative modality in the treatment 
of recurrent endometrioma. Ikuta et al used 
ethanol for 5 minutes and aspirated it all. The 
recurrence rate was 11.1% (16). Yazbeck et al 
left ethanol for 10 minutes, and the recurrence 
rate was 12.9% at a mean time of 10 months 
after sclerotherapy. In addition they 
demonstrated that the number of mature 
oocytes was higher in the ethanol group (9). 
Similarly, Salem et al reported ethanol 
sclerotherapy may improve IVF outcome (19). 
Hsieh et al mentioned the retention of ethanol 
in the endometrioma was more effective than 
the removal of alcohol. Hsieh reported the 
recurrence rate was 13.3% in retention of 
ethanol versus 32.1% when ethanol was 
removed during one year (8). 
Zhu et al reported that the monthly 
repetition of aspiration could decrease the 
recurrence rate from 91.5% to 27.9% after two 
years (6). In our study, ethanol was left for ten 
minutes and the recurrence rate was 20% in 6 
months, as in some other studies. Although 
there was no significant difference between 
the IVF outcomes of the two groups, some 
good results were achieved in favor of the 
ethanol group. It appears that the presence of 
bilateral endometrioma during IVF treatment is 
not associated with reduced embryo quality 
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(20). Koike et al observed that the number of 
good-quality embryos was higher in the 
ethanol group(17).  
Also, we had significantly good-quality 
embryos in our study group. But Okagaki et al 
reported unusual adhesion in four patients 
who had experienced ethanol sclerotherapy 
which might have been reasoned by the 
leakage of endometrioma or ethanol (21). The 
epithelial cells lining the cyst walls play a 
critical function. When ethanol contacted the 
cyst walls, the coagulation cascade was 
activated and inflammatory mediators and 
fibrosis were produced. It was critical for the 
adhesion of the cyst walls and for the 
avoidance of reaccumulation of the 
endometrioma (13, 22). It has also been 
reported that ethanol treatment induces 
dehydration of the surrounding tissues, 
leading to a loss of function in these tissues 
(17).  
Chang and Hsieh reported a raise in the 
amount of antral follicles after ethanol 
sclerotherapy. When endometrioma was in 
the vicinity of follicles, it could make the 
oocyte retrieval more complicated and 
contaminate the follicular fluid with the content 
of the endometrioma. After sclerotherapy, the 
negative mechanical pressure of 
endometrioma was eliminated from the 
folliculogenic property of the ovary, and a free 
space was created for the dominant follicles.  
Moreover, the ovarian blood supply got 
better (8, 23, 24). In the endometrium, 
aromatase P450 is also stated under 
pathological forms, and local estrogen 
biosynthesis is considered to be essential to 
the pathophysiology of a diversity of uterine 
disorders, including fibroids, endometriosis, 
and adenomyosis (25). The decreased 
expression of HOXA10 may designate 
impaired endometrial receptivity in patients 
with endometriosis (26, 27).  
A probable limit of this study is associated 
to the period for the follow-up evaluation. It 
can be quarreled that a 3-6 month period is 
too short for recurrence. In contrast, 
endometriosis may progress over time. 
Therefore a longer follow-up could postpone 
ovarian stimulation. An attempt for conception 
as soon as possible after surgery seems 
advisable since waiting is tantamount to a 
lower pregnancy rate and a higher rate of 
recurrence (28). Ethanol sclerotherapy has 
been a suitable replacement for surgery in 
some patients, especially before IVF. This 
result poses a question in mind as how 
HOXA10 and aromatase P450 will change 
after doing sclerotherapy. It can be a matter of 
scrutiny in future clinical trials. 
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